Cevimeline
Names | |
---|---|
Pronunciation | se vim' e leen[1] |
Trade names | Evoxac |
IUPAC name
| |
Clinical data | |
Drug class | Muscarinic agonist[1] |
Main uses | Dry mouth[1] |
Side effects | Increased sweating, runny nose, nausea, diarrhea, headaches, dizziness, visual disturbances, tiredness[1] |
WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
Pregnancy category |
|
Routes of use | By mouth (capsules) |
External links | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608025 |
Legal | |
Legal status |
|
Pharmacokinetics | |
Protein binding | <20% |
Chemical and physical data | |
Formula | C10H17NOS |
Molar mass | 199.31 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Cevimeline, sold under the brand name Evoxac, is a medication used to treat dry mouth due to Sjögren's syndrome or radiation therapy.[1] It is similar to pilocarpine.[2] It is taken by mouth.[1]
Side effects are usually mild and may include increased sweating, runny nose, nausea, diarrhea, headaches, dizziness, visual disturbances, and tiredness.[1] Safety in pregnancy is unclear.[2] It is a muscarinic agonist, which results in increased saliva production.[1]
Cevimeline was approved for medical use in the United States in 2000.[2] It is available as a generic medication.[3] In the United States a month of medication costs about 52 USD as of 2021.[3]
Medical use
Dosage
The typical dose is 30 mg three times daily.[1]
Side effects
Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[4]
Contraindications include asthma and angle closure glaucoma.
Mechanism of action
By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.
See also
- Pilocarpine — a similar parasympathomimetic medication for dry mouth (xerostomia)
- Bethanechol — a similar muscarinic parasympathomimetic with longer-lasting effect
References
- 1 2 3 4 5 6 7 8 9 "Cevimeline". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 3 January 2022.
- 1 2 3 "Cevimeline Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 3 January 2022.
- 1 2 "Cevimeline Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 26 September 2016. Retrieved 3 January 2022.
- ↑ Archived 2017-09-30 at the Wayback Machine MedicineNet: Cevimeline. Accessed 10/12/2007
External links
Identifiers: |
---|